Silo Pharma EBITDA TCAC 5A

Que fait Silo Pharma ? Silo Pharma Inc generates revenue through the development and licensing of intellectual property related to psychedelic-assisted therapies for neurological and mental health conditions. The company acquires and develops technology rights from universities and researchers, focusing on treatments for PTSD, Alzheimer's disease, and rare neurological disorders. It secures funding via sponsored research agreements, such as the one with Columbia University, which grants it an option to license patents and inventions involving Ketamine combinations for Alzheimer’s and stress-induced disorders. The primary customers are pharmaceutical companies seeking to expand their therapeutic portfolios with psychedelic-based treatments. The firm's products include intellectual property rights for psychedelic drug applications, particularly psilocybin and Ketamine-based therapies, targeting depression, mental health issues, and neurological disorders. These assets are developed through partnerships with academic institutions like Columbia University, where the company gains access to patented technologies for treating Alzheimer’s and stress-related conditions. The company does not sell products directly but licenses its IP to larger pharmaceutical firms for further development and commercialization. Silo Pharma targets the biopharmaceutical sector, specifically companies developing treatments for rare neurological disorders and mental health conditions. Its intellectual property is positioned to address unmet medical needs in PTSD, Alzheimer's, and depression, with a focus on psychedelic-assisted therapies. The company’s revenue model relies on licensing agreements and sponsored research deals, avoiding direct product sales. Columbia University remains a key partner in its IP acquisition strategy for Alzheimer's and stress disorder treatments. Silo Pharma est l'une des entreprises les plus populaires sur Eulerpool.